Comment on: Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis
Clin Cardiol
.
2022 Jul;45(7):685-686.
doi: 10.1002/clc.23851.
Epub 2022 May 30.
Authors
Jian-Hao Deng
1
,
Jia-Xing Zhang
2
Affiliations
1
Pharmacy Department, Longyan Second Hospital, Longyan, China.
2
Pharmacy Department, Guizhou Provincial People's Hospital, Guiyang, China.
PMID:
35634752
PMCID:
PMC9286330
DOI:
10.1002/clc.23851
No abstract available
Publication types
Letter
Comment
MeSH terms
Allopurinol / adverse effects
Febuxostat / adverse effects
Gout Suppressants / adverse effects
Gout* / drug therapy
Humans
Hyperuricemia* / drug therapy
Substances
Gout Suppressants
Febuxostat
Allopurinol